GlassScriptPhysician profile
Haydee Birkhimer
NPI 1497046791
$9,554.09
in general payments reported to CMS, 2019-2025
35 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 90% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
See the full distribution for Acute Care (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,454 · 2022: $988 · 2023: $1,111 · 2024: $4,870 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,112.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $4,163.17 | 2024 | M22 |
| Novo Nordisk INC | $1,080.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,009.29 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $506.39 | 2021-2025 | |
| Abbvie INC. | $492.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $410.47 | 2021-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $267.26 | 2022 | |
| Glaxosmithkline, LLC. | $264.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $257.97 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.30 | 2023-2025 | Jardiance |
| Mayne Pharma Commercial LLC | $145.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.03 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.69 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $61.64 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $52.41 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.36 | 2021-2024 | Xarelto |
| Dexcom, INC. | $41.92 | 2023-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $41.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.96 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $32.79 | 2025 | |
| Genzyme Corporation | $28.46 | 2025 | |
| Organon LLC | $26.45 | 2022 | |
| Corcept Therapeutics | $25.24 | 2025 | Korlym |
| Allergan, INC. | $22.12 | 2022 | |
| Incyte Corporation | $22.06 | 2023 | Opzelura |
| Amarin Pharma, INC. | $21.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.63 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2021 | |
| Philips North America LLC | $18.68 | 2022 | |
| Horizon Therapeutics Plc | $17.35 | 2021 | |
| Biogen, INC. | $15.88 | 2024 | Spinraza |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2021 | |
| Medtronic, INC. | $15.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.74 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haydee Birkhimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.